Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS

Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas. Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting Sy...

Full description

Bibliographic Details

Published in:	Frontiers in pharmacology Vol. 15; p. 1454418
Main Author:	Li, Lin
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 07.01.2025
Subjects:	adverse reactions FAERS neurofibromatosis type I Pharmacology rare diseases selumetinib neurofibromatosis type I rare diseases FAERS selumetinib adverse reactions
ISSN:	1663-9812, 1663-9812
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!